Companies › Orum Therapeutics USA
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ORM-1153 anti-CD123 antibody-drug conjugate | IL3RA | Phase 1 | CD123+ Acute Myeloid Leukemia | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07809906 | ORM-1153 | Phase 1 | CD123+ Acute Myeloid Leukemia | Oncology | Dec 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.